Document is current
Any future updates will be listed below
-
Authors
Malacrida, Beatrice
Elorbany, Samar https://orcid.org/0000-0001-8342-0948
Laforêts, Florian
Karim, Faisal
Bryan-Ravenscroft, Rachel C.
Sideris, Michail
Joy, Joash D. https://orcid.org/0000-0001-5700-2582
Kotantaki, Panoraia https://orcid.org/0000-0003-1098-9994
Skingsley, Sophie L. P.
Heath, Owen M.
Manchanda, Ranjit https://orcid.org/0000-0003-3381-5057
Maniati, Eleni https://orcid.org/0000-0001-6993-9890
Balkwill, Frances R. https://orcid.org/0000-0002-5587-9759
- License Information
-
More Information
Article History
Received: 9 April 2025
Accepted: 24 February 2026
First Online: 25 March 2026
Competing interests
: B.M. and F.R.B. declare research funding from AstraZeneca. F.R.B. declares being on the Scientific Advisory Board of iOmx Therapeutics AG. R.M. reports research funding grants from GSK, Yorkshire Cancer Research, Rosetrees Trust outside the submitted work, and honoraria for advisory board membership from Astrazeneca/MSD/GSK/EGL. The remaining authors declare declare no competing interests.
